32 h. ago Glenmark's IGI Eyes US Listing After Cancer Drug Deal With AbbVie, Says Chairman Glenn Saldanha

Saldanha said it could take 4-5 years to commercialise ISB 2001.

Politics

35 h. ago India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal

India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal  Reuters

Politics

37 h. ago Glenmark Arm IGI's AbbVie Deal Unfolds Blockbuster Potential, Says Motilal Oswal

Based on the contours of the deal, Motilal Oswal adds an NPV of Rs 470 per share to the 27x 12M forward base business earnings to arrive at a target price of Rs 2,430.

Politics

37 h. ago Glenmark Pharma Shares Hit Life High After License Deal With AbbVie For Cancer Drug

IGI has partnered with AbbVie to grant exclusive rights to globally develop, manufacture, and commercialise ISB 2001 across North America, Europe, Japan, and Greater China.

Events

37 h. ago Glenmark Pharma's Mega Deal With AbbVie Has Brokerages Mixed

HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama maintains a more cautious outlook.

Politics

50 h. ago Glenmark Unit Signs Exclusive Licensing Pact With AbbVie For Cancer Drug

Under the pact, Glenmark's innovation arm has partnered with AbbVie to globally manufacture ISB 2001, a drug used in cancer treatment.

Events